Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $245 from $226 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $234 from $225 at Barclays
- Jazz Pharmaceuticals price target raised to $252 from $209 at Baird
- Jazz Pharmaceuticals price target raised to $275 from $220 at TD Cowen
- Jazz Pharmaceuticals price target raised to $239 from $227 at Raymond James
- Jazz Pharmaceuticals Signals Confidence After Record Quarter